Ekso Bionics (NASDAQ:EKSO) Posts Earnings Results, Misses Estimates By $0.02 EPS

Ekso Bionics (NASDAQ:EKSO) announced its quarterly earnings results on Monday. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02), Yahoo Finance reports. Ekso Bionics had a negative net margin of 68.41% and a negative return on equity of 92.08%. The firm had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $6.00 million. During the same quarter in the prior year, the business posted ($0.24) EPS.

Ekso Bionics Trading Down 2.9 %

NASDAQ:EKSO opened at $0.93 on Thursday. The firm has a 50 day moving average of $1.11 and a 200 day moving average of $1.15. The company has a quick ratio of 1.77, a current ratio of 2.42 and a debt-to-equity ratio of 0.36. Ekso Bionics has a 52 week low of $0.83 and a 52 week high of $3.13. The stock has a market capitalization of $16.94 million, a price-to-earnings ratio of -0.96 and a beta of 1.45.

Wall Street Analysts Forecast Growth

A number of research firms have commented on EKSO. HC Wainwright cut their target price on shares of Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Tuesday. Lake Street Capital cut their price objective on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, StockNews.com assumed coverage on Ekso Bionics in a report on Saturday, October 26th. They set a “hold” rating for the company.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.